Cargando…

Expected Impact of Biosimilars on the Pharmaceutical Companies

Detalles Bibliográficos
Autores principales:	Golshani, Shiva, Ali Faramarzi, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Shiraz University of Medical Sciences 2021
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438344/ https://www.ncbi.nlm.nih.gov/pubmed/34539015 http://dx.doi.org/10.30476/IJMS.2021.92314.2356

Ejemplares similares

Buyouts of Indian Pharmaceutical Companies by Multinational Pharmaceutical Companies: An Issue of Concern
por: Sreedhar, D, et al.
Publicado: (2011)

Pharmaceutical companies as the funding sources for continuing medical education
por: Kanchan, Tanuj
Publicado: (2015)

Good Pharmacovigilance Practice: Accountability of Ayurvedic Pharmaceutical Companies
por: Sharma, Rohit, et al.
Publicado: (2017)

Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?
por: Kobashi, Yurie, et al.
Publicado: (2019)

Good pharmacovigilance practice: Need of the hour from pharmaceutical companies
por: Bhati, Neha, et al.
Publicado: (2015)

The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyond
por: Chang, Lin-Chau
Publicado: (2019)

Coronavirus disease 2019 experts appearing on Japanese television: their characteristics and financial conflicts of interest with pharmaceutical companies
por: Murayama, Anju, et al.
Publicado: (2021)

Involvement of pharmaceutical companies at scientific meetings
por: Brink, Andries
Publicado: (2010)

Biosimilars: The naming puzzle
por: Gaur, Rajneesh Kumar
Publicado: (2015)

Letter to the Editor Regarding “Esterified Hyaluronic Acid Placed in the Middle Ear Does Not Improve Outcomes in Cholesteatoma Surgery”
por: Faramarzi, Mohammad, et al.
Publicado: (2023)

Ophthalmic biosimilars: Lessons from India
por: Sharma, Ashish, et al.
Publicado: (2019)

The influence of pharmaceutical companies
por: Migone, Paolo
Publicado: (2017)

Gender and racial bias in drug promotional material distributed by pharmaceutical companies
por: Jaykaran,, et al.
Publicado: (2012)

Biosimilar insulins: An unavoidable option in South-East Asia
por: Kaduskar, Prashant Ulhas
Publicado: (2016)

Biosimilars: Company Strategies to Capture Value from the Biologics Market
por: Calo-Fernández, Bruno, et al.
Publicado: (2012)

Pharmacovigilance in pharmaceutical companies: An overview
por: Mammì, Maria, et al.
Publicado: (2013)

Impacts of international sanctions on Iranian pharmaceutical market
por: Cheraghali, Abdol Majid
Publicado: (2013)

Comment on “Biosimilar FSH preparations- are they identical twins or just siblings?”
por: Strowitzki, Thomas, et al.
Publicado: (2016)

Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”
por: Webster, Christopher J., et al.
Publicado: (2018)

Tobacco companies are booming despite an economic depression
por: He, Peisen, et al.
Publicado: (2009)

Pharmacovigilance obligations of the pharmaceutical companies in India
por: Arora, Deepa
Publicado: (2008)

Regulating pharmaceutical companies’ financial largesse
por: Avraham, Ronen, et al.
Publicado: (2018)

The Pharmaceutical Company Approach to Antibiotic Policies
por: White, Anthony R.
Publicado: (2005)

Ethics, gastroenterologists, and pharmaceutical and equipment companies
por: Roberts‐Thomson, Ian C
Publicado: (2020)

Medical Affairs in Pharmaceutical Companies and Related Pharmaceutical Regulations in Japan
por: Maeda, Hideki
Publicado: (2021)

Response to Comments on the CAG/CCC Position Statement on Biosimilars for Inflammatory Bowel Disease
por: Moayyedi, Paul, et al.
Publicado: (2020)

Drug promotional literature distributed by pharmaceutical companies: Do they provide enough information to ascertain their validity?
por: Jaykaran,, et al.
Publicado: (2011)

bDMARDs retention rate in the biosimilar era: A real-life monocentric study
por: Becciolini, Andrea, et al.
Publicado: (2021)

Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”
por: Hassett, Brian, et al.
Publicado: (2018)

Comment on Hernandez-Vasquez et al., a bibliometric analysis of the global research on biosimilars
por: Cohen, Hillel P.
Publicado: (2018)

Comment on: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”
por: Pires, Antonio, et al.
Publicado: (2018)

Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure
por: Vogler, Sabine, et al.
Publicado: (2021)

Expect the unexpected
por: Rathee, Manu
Publicado: (2014)

Pharmaceutical Company Targets and Strategies to Address Climate Change: Content Analysis of Public Reports from 20 Pharmaceutical Companies
por: Booth, Amy, et al.
Publicado: (2023)

Impact of COVID-19 Pandemic on the Mental Health of Returning Employees in Labor-Intensive Companies: A Study Based on Repeated Surveys
por: LIU, Yu, et al.
Publicado: (2022)

Bayesian Statistical Methods and Their Valuable Applications in the Pharmaceutical Sciences
por: MADADIZADEH, Farzan, et al.
Publicado: (2016)

Impact of Corporate Reputation on Brand Differentiation: An Empirical Study from Iranian Pharmaceutical Companies
por: vahabzadeh, Afshin, et al.
Publicado: (2017)

Response to: Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”
por: Miranda-Hernández, Mariana P., et al.
Publicado: (2018)

A Case of Isotretinoin Therapy-Refractory Folliculitis Decalvans Treated Successfully with Biosimilar Adalimumab (Exemptia)
por: Shireen, Furtado, et al.
Publicado: (2018)

Error in Payments From Some Pharmaceutical Companies
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hmqnp2aknrvupfi6dq6ve83ofg